Dr. John Cush RheumNow
11 months 3 weeks ago
PT in RA - Metanalysis of 17 RCTs, 1362 pts Rx w/ aerobic/resistance exercise, hydrotherapy, manual Rx, electrotherapy, multimodal Rx. 5 RCTs (n 307) signif reduced pain (SMD −0.347; interpreted as a small to medium effect favoring PT. https://t.co/UJGSGrgMV0 https://t.co/n4DzMSm9iJ
The American Journal of Medicine and Dr. Joseph S. Alpert have published a long list of smart, insightful and inspirational aphorisms from some of the greatest leaders in internal medicine. These aphorisms are timeless and should be passed from one generation of physicians to the next.
Dr. John Cush RheumNow
11 months 3 weeks ago
Retrospective UK study of CPRD dataset (2012-2023) found 22 829 incident CTD Dx (81% F). Over time incidence SLE & Systemic Sclerosis fell, Sjogrens & MCTD stable, & IIM rose 3.23–4.31/100K. IIM had highest mortality (28/1000 py), followed by SSc, SLE, MCTD; lowest SjD (9.7)
Dr. John Cush RheumNow
11 months 3 weeks ago
Venous thromboembolism (VTE) risk goes up w/ age, obesity, estrogens; BUT a UK primary care database shows VTE risk signif higher in RA (n 23K) vs matched controls (n 94K): adj HR 1.46. Absolute VTE risk higher w/ age & BMI, but VTE higher in younger v older; normal vs. Hi BMI: https://t.co/htI2YqiF0c
Dr. John Cush RheumNow
11 months 3 weeks ago
Advances in Still's disease Rx:
- using IL-1 or IL-6 inhibitors 1st line
- New FDA approval of emapalumab (IFNg) for MAS
- unclear if biologics can cause lung probs in Stills https://t.co/zSqTcOSVGE https://t.co/qefCt5b7qh
Dr. John Cush RheumNow
11 months 3 weeks ago
French OL trial of PCV13 vaccination in 248 early, DMARD Naive RA pts starting MTX @ same time or after 1 month delay. 1 mo delay in MTX resulted in significantly higher responses (46%, 65%) vs. pts vax while taking MTX. Signif responses seen 1 yr later. RA activity equal betw. https://t.co/AnqK89ZJtE
Dr. John Cush RheumNow
11 months 3 weeks ago
JAKne? Study of 2183 IBD pts on JAK inhib, 272 developed acne. Crude prevalence: 16% upadacitinib, 4% tofacitinib, 2% filgotinib (dose-dependent w/ UPA & Tofa). JAKne in pts 30–50 yrs; mild-moderate severity; in 1st 3 mos. Higher risk w/ prior hx acne vulgaris (OR 4.9) https://t.co/nz8F2lBwe5
Dr. John Cush RheumNow
11 months 3 weeks ago
Repurposing & Pipeline (8.8.2025)
Dr. Jack Cush reviews the news, reports, pipeline and drug repurposing on this week’s podcast.
https://t.co/Hx1aAdiTOy https://t.co/gwyDweXIbS
Analysis of data from two large, prospective cohort studies show that knee chondrocalcinosis was associated with an increased risk of incident knee osteoarthritis.
Dr. John Cush RheumNow
11 months 3 weeks ago
Dermatomyositis Reviewed
Researchers from the University of Pennsylvania have published an open-access review of dermatomyositis (DM) - its manifestations, hallmark cutaneous features, etiopathogenesis and treatment options.
https://t.co/Dm85RL99UU https://t.co/zHVBreQi58
Dr. John Cush RheumNow
11 months 3 weeks ago
Mid East/N African Survey on #SpA referrals.
- 190 Rheum responded (68% consultants, 53% tertiary,95% urban)
- 89% reported delay in axSpA presenting (most: Ortho, FP, internists)
- 2/3 Dx challenges
- > 60^ Pt non-adherence (side effects or Sx improvement) https://t.co/6jBdOqp2gM
Dr. John Cush RheumNow
11 months 4 weeks ago
Mayo study of 659 incident RA pts finds Multimorbidity predicted 29% (OR:1.29) higher odds of RA flare, & 34% lower (OR:0.66) odds of remission. RA Flares assoc w/ female, smoking, younger age shorter Dz duration, but not seropositivity. Remission assoc w/ male, not smoking, https://t.co/yEwkQ63zIh
RheumNow surveyed clinicians worldwide on how their rheumatology practice, treatment decisions, and career outlooks have changed over the past 20 years. 242 respondents (68% from the USA) shared their perspectives on the changing landscape of rheumatoid arthritis care, practice patterns, and professional development.
The ACR has published a formal international consensus guidance on VEXAS as a resource for clinicians seeking to understand the disease and its management.
Dr. John Cush RheumNow
11 months 4 weeks ago
Inefficiencies of ANA Testing
The Journal of Rheumatology has published an analysis of antinuclear antibody (ANA) multiplex testing showing its nonspecific utility and poor rate of return in identifying ANA-associated autoimmune rheumatic disease (ARDs). https://t.co/hojdPPtCcI
